WO2002096868A3 - Preparation of 17-phenyl- 18, 19, 20- trinor-pgf2a and its derivatives - Google Patents

Preparation of 17-phenyl- 18, 19, 20- trinor-pgf2a and its derivatives Download PDF

Info

Publication number
WO2002096868A3
WO2002096868A3 PCT/IL2002/000422 IL0200422W WO02096868A3 WO 2002096868 A3 WO2002096868 A3 WO 2002096868A3 IL 0200422 W IL0200422 W IL 0200422W WO 02096868 A3 WO02096868 A3 WO 02096868A3
Authority
WO
WIPO (PCT)
Prior art keywords
trinor
phenyl
derivatives
pgf2a
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2002/000422
Other languages
French (fr)
Other versions
WO2002096868A2 (en
Inventor
Arie L Gutman
Gennady Nisnevich
Marina Etinger
Igor Zaltzman
Lev Yudovitch
Boris Pertsikov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finetech Ltd
Original Assignee
Finetech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/478,849 priority Critical patent/US7157590B2/en
Application filed by Finetech Ltd filed Critical Finetech Ltd
Priority to CN02811151.6A priority patent/CN1774417A/en
Priority to JP2003500048A priority patent/JP2004529973A/en
Priority to HU0400447A priority patent/HUP0400447A2/en
Priority to CA002448631A priority patent/CA2448631A1/en
Priority to EP02735939A priority patent/EP1397347A2/en
Publication of WO2002096868A2 publication Critical patent/WO2002096868A2/en
Publication of WO2002096868A3 publication Critical patent/WO2002096868A3/en
Anticipated expiration legal-status Critical
Priority to US11/125,164 priority patent/US7166730B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention provides a new and effective process for the synthesis of 17-phenyl-18,19,20-trinor-PGF2α and its derivatives, including the anti-glaucoma drugs Bimatoprost and Latanoprost. The benefit of the present invention rises inter alia from the fact that a major intermediate involved in the synthesis of the above compounds may be isolated from a mixture containing also an undesired isomer, by crystallization. In addition, the undesired isomer may be oxidized to give the starting compound, which is then recycled.
PCT/IL2002/000422 2000-01-27 2002-05-30 Preparation of 17-phenyl- 18, 19, 20- trinor-pgf2a and its derivatives Ceased WO2002096868A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/478,849 US7157590B2 (en) 2001-05-31 2002-05-03 Process for the preparation of 17-phenyl-18,19,20-thinor-pgf 2a and its derivatives
CN02811151.6A CN1774417A (en) 2001-05-31 2002-05-30 Preparation method of 17-phenyl-18,19,20-destrimethyl-prostaglandin F2α and its derivatives
JP2003500048A JP2004529973A (en) 2001-05-31 2002-05-30 New method for producing 17-phenyl-18,19,20-trinor-PGF2α and its derivatives
HU0400447A HUP0400447A2 (en) 2001-05-31 2002-05-30 A new process for the preparation of 17-phenyl-18,19,20-trinor-pgf2a and its derivatives
CA002448631A CA2448631A1 (en) 2001-05-31 2002-05-30 Preparation of 17-phenyl- 18, 19, 20- trinor-pgf2.alpha. and its derivatives
EP02735939A EP1397347A2 (en) 2001-05-31 2002-05-30 Preparation of 17-phenyl- 18, 19, 20- trinor-pgf2a and its derivatives
US11/125,164 US7166730B2 (en) 2000-01-27 2005-05-10 Process for the preparation of prostaglandin derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL143477 2001-05-31
IL143477A IL143477A (en) 2001-05-31 2001-05-31 Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10478849 A-371-Of-International 2002-05-30
US11/125,164 Continuation-In-Part US7166730B2 (en) 2000-01-27 2005-05-10 Process for the preparation of prostaglandin derivatives

Publications (2)

Publication Number Publication Date
WO2002096868A2 WO2002096868A2 (en) 2002-12-05
WO2002096868A3 true WO2002096868A3 (en) 2003-10-23

Family

ID=11075455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000422 Ceased WO2002096868A2 (en) 2000-01-27 2002-05-30 Preparation of 17-phenyl- 18, 19, 20- trinor-pgf2a and its derivatives

Country Status (8)

Country Link
US (1) US7157590B2 (en)
EP (1) EP1397347A2 (en)
JP (1) JP2004529973A (en)
CN (1) CN1774417A (en)
CA (1) CA2448631A1 (en)
HU (1) HUP0400447A2 (en)
IL (1) IL143477A (en)
WO (1) WO2002096868A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109371B2 (en) 2004-01-05 2006-09-19 Johnson Matthey Public Limited Company Prostaglandin synthesis
US8906962B2 (en) 2000-03-31 2014-12-09 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143477A (en) * 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
IL134241A (en) 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
SI1480949T1 (en) * 2002-03-01 2015-09-30 Allergan, Inc. Preparation of prostamides
PL212658B1 (en) * 2005-04-18 2012-11-30 Inst Farmaceutyczny Method for obtaining the derivatives of 13,14-dihydro-PGF₂α
WO2007041273A2 (en) * 2005-09-29 2007-04-12 Eastar Chemical Corp. Process for the production of intermediates for making prostaglandin derivatives such as latanoprost, travaprost, and bimatoprost
IL177762A0 (en) 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
ATE496903T1 (en) 2007-02-01 2011-02-15 Allergan Inc THIOPHENE DERIVATIVES AS MEDICATIONS FOR THE TREATMENT OF OCCULAR HYPERTENSION
US7964595B2 (en) 2008-01-18 2011-06-21 Allergan, Inc. Thiophenyl prostaglandin derivatives for treating glaucoma and ocular hypertension
CN101555221B (en) * 2008-04-09 2013-01-23 明德国际仓储贸易(上海)有限公司 Producing method of prostaglandin F-type derivant
EP2135860A1 (en) 2008-06-20 2009-12-23 Sandoz AG Improved process for the production of bimatoprost
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
JP2012507552A (en) * 2008-10-29 2012-03-29 アエリエ・ファーマシューティカルズ・インコーポレーテッド Amino acid salt of prostaglandin
AU2010256558B2 (en) 2009-06-03 2013-10-03 Forsight Labs, Llc Anterior segment drug delivery
US8476471B2 (en) 2009-07-13 2013-07-02 Irix Pharmaceuticals, Inc. Synthesis of prostanoids
EP2488508A4 (en) 2009-10-16 2013-04-24 Cayman Chemical Co Inc Process for the preparation of f-series prostaglandins
WO2011050638A1 (en) 2009-11-02 2011-05-05 上海天伟生物制药有限公司 A crystalline form of bimatoprost, preparation method and use thereof
WO2011055377A1 (en) * 2009-11-05 2011-05-12 Biocon Limited A novel process for the preparation of prostaglandins and intermediates thereof
CA2781698A1 (en) * 2009-11-23 2011-05-26 Allergan, Inc. 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
JP2013526572A (en) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド Drug delivery device for the delivery of eye treatments
WO2012011128A1 (en) * 2010-07-23 2012-01-26 Aptuit Laurus Private Limited Preparation of prostaglandin derivatives
EP2495235B1 (en) 2011-03-04 2015-08-05 Newchem S.p.A. Process for the synthesis of prostaglandins and intermediates thereof
CN106278982B (en) * 2011-06-02 2019-06-14 奇诺因私人有限公司 Novel method for the preparation of prostaglandin amides
RU2740680C2 (en) 2011-09-14 2021-01-19 Форсайт Вижн5, Инк. Eye inserter device and methods
JP2012246301A (en) * 2012-08-10 2012-12-13 Cayman Chemical Co Inc Method for preparing prostaglandins f
CN103664726A (en) * 2012-08-31 2014-03-26 南京华狮化工有限公司 Deuterated bimatoprost or derivative thereof and preparation method and application of deuterated bimatoprost or derivative thereof
EP2911623B1 (en) 2012-10-26 2019-08-14 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
HU230744B1 (en) * 2012-11-30 2018-01-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. New process for the production of travoprost
JP2016515583A (en) 2013-03-27 2016-05-30 フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． Ocular inserts and how to use them
CN103288698A (en) * 2013-05-07 2013-09-11 北京洛斯顿精细化工有限公司 Novel method for synthetizing prostaglandin analogue
KR102311896B1 (en) 2013-09-30 2021-10-14 패턴 에이피아이 서비시즈 인코포레이티드 Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
CN103570549B (en) * 2013-10-11 2016-01-27 天泽恩源（天津）制药有限公司 A kind of method of synthesizing tafluprost
CN103601708B (en) * 2013-12-11 2015-06-17 武汉武药科技有限公司 Preparation method of prostaglandin medicine impurity
EP3091985B1 (en) 2014-01-10 2024-05-08 Manistee Therapeutics, Inc. Prostanglandins for topical use in the treatment of migraines.
CN103804195B (en) * 2014-01-26 2016-06-15 天泽恩源（天津）制药有限公司 A kind of method synthesizing tafluprost
HU231214B1 (en) * 2014-03-13 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. A new process for the production of high purity prostaglandins
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
EP3235810A1 (en) 2016-04-19 2017-10-25 Gentec, S.A. Process for the preparation of bimatoprost
CN106810484B (en) * 2016-12-28 2019-04-12 宁波第二激素厂 The synthetic method of tromethamine dinoprost
PL3949962T3 (en) * 2017-07-18 2024-03-18 Katholieke Universiteit Leuven Compositions against candida infections
CN112481313B (en) * 2020-11-23 2022-08-12 江苏阿尔法药业股份有限公司 A kind of enzymatic synthesis method of bimeprost intermediate
CN112645861A (en) * 2020-12-21 2021-04-13 上海彩迩文生化科技有限公司 Method for separating carboprost 15-position isomer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055101A2 (en) * 2000-01-27 2001-08-02 Finetech Laboratories Ltd. A new process for the preparation of latanoprost
WO2002096868A2 (en) * 2001-05-31 2002-12-05 Finetech Laboratories Ltd. Preparation of 17-phenyl- 18, 19, 20- trinor-pgf2a and its derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931279A (en) 1973-05-21 1976-01-06 The Upjohn Company 5-Oxa prostaglandin F2.sub.α analogs
DE2517773A1 (en) 1975-04-18 1976-10-28 Schering Ag NEW 11-OXO-PROSTAGLANDIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION
US5233537A (en) * 1991-06-11 1993-08-03 The United States Of America As Represented By The Secretary Of The Navy Very low frequency and low frequency transmitting antenna parameter monitoring system
HU212570B (en) 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
DE4412635A1 (en) 1994-04-13 1995-10-19 Putzmeister Maschf Remote control arrangement, in particular for conveying, spraying and distributing machines for concrete and mortar
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
EP0930296B2 (en) 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorinated prostaglandin derivatives and medicines
JP3480549B2 (en) 1996-12-26 2003-12-22 参天製薬株式会社 Difluoroprostaglandin derivatives and uses thereof
AU2001261019A1 (en) 2000-05-15 2001-11-26 Pharmacia And Upjohn Company Process and intermediates to prepare latanoprost
CA2453631A1 (en) 2001-07-17 2003-01-30 Pharmacia & Upjohn Company Process and intermediates to prepare latanoprost

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055101A2 (en) * 2000-01-27 2001-08-02 Finetech Laboratories Ltd. A new process for the preparation of latanoprost
WO2002096868A2 (en) * 2001-05-31 2002-12-05 Finetech Laboratories Ltd. Preparation of 17-phenyl- 18, 19, 20- trinor-pgf2a and its derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IGUCHI S ET AL: "Diisobutylaluminum 2,6-di-t-butyl-4-methylphenoxide. Novel stereoselective reducing agent for prostaglandin synthesis", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN 1981 JAPAN, vol. 54, no. 10, 1981, pages 3033 - 3041, XP002246788 *
RESUL B ET AL: "PHENYL-SUBSTITUTED PROSTAGLANDINS: POTENT AND SELECTIVE ANTIGLAUCOMA AGENTS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 36, no. 2, 1993, pages 243 - 248, XP000673914, ISSN: 0022-2623 *
SCHAAF T K: "N-(METHANESULFONYL)-16-PHENOXYPROSTAGLANDINCARBOXAMIDES : TISSUE- SELECTIVE, UTERINE STIMULANTS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 24, no. 11, 1 November 1981 (1981-11-01), pages 1353 - 1359, XP000652663, ISSN: 0022-2623 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906962B2 (en) 2000-03-31 2014-12-09 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US9579270B2 (en) 2000-03-31 2017-02-28 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US7109371B2 (en) 2004-01-05 2006-09-19 Johnson Matthey Public Limited Company Prostaglandin synthesis

Also Published As

Publication number Publication date
IL143477A0 (en) 2002-04-21
WO2002096868A2 (en) 2002-12-05
HUP0400447A2 (en) 2005-04-28
CA2448631A1 (en) 2002-12-05
US7157590B2 (en) 2007-01-02
JP2004529973A (en) 2004-09-30
EP1397347A2 (en) 2004-03-17
CN1774417A (en) 2006-05-17
US20040171873A1 (en) 2004-09-02
IL143477A (en) 2009-07-20

Similar Documents

Publication Publication Date Title
Munavalli et al. Trifluoromethylsulfenylation of masked carbonyl compounds
NO20071498L (en) Substituted acyl hydroxamic acids as well as methods for reducing the TNFα level
WO2001090106A3 (en) Tryasolyl tropane derivatives as ccr5 modulators
CA2429844A1 (en) Mch antagonists and their use in the treatment of obesity
EA200301306A1 (en) DERIVATIVES 1-PHENYLSULFONIL-1,3-DIHYDRO-2H-INDOL-2-SHE, THEIR PRODUCTION AND THEIR THERAPEUTIC APPLICATION
BG105547A (en) Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
CA2416867A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
WO2003013512A3 (en) Crystalline forms of fluvastatin sodium
EA200201264A1 (en) 5-CHLOR-3 (4-METHESULPHONYLPHENYL) -6'-METHYL- [2,3 '] BIPYRIDINYL IN PURE CRYSTALLINE AND SYNTHESIS METHOD
WO2001057014A3 (en) Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
WO2003011849A8 (en) Process for the production of beraprost and its salts
WO1997031016A3 (en) New inhibitors of sh2-mediated processes
EA200200939A1 (en) METHOD OF OBTAINING CYTALOPRAMA
KR960031442A (en) Use of phenylcyclohexylcarboxamide
AU2001255646A1 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
EP1253139A3 (en) Multioligoanilinated fullerenes
EP1199308A3 (en) Process for the preparation of imidazodiazepine intermediates
WO2002059089A3 (en) Process for the preparation of heterocyclic indene analogs
NO20033049D0 (en) Process for the preparation of (+/-) trans-4-p-fluorophenyl-3-hydroxymethyl-1
WO2003000016A3 (en) Highly concentrated organic compound emulsions and methods of use
NO962294L (en) Crystalline, polymorphic form of (S, S, S) -N- (1- [2-carboxy-3- (N2-mesyllysylamino) propyl α-1-cyclopentylcarbonyl) tyrosine
WO2000020386A1 (en) Stannane synthesis of prostanoids
AR037493A1 (en) PROCESS FOR THE PREPARATION OF CITALOPRAM HYDROBROMIDE
IT1299582B1 (en) PROCEDURE FOR THE PREPARATION OF 13-CIS-RETINOIC ACID
WO2004078109A3 (en) PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ανβ3 RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2448631

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002309221

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2034/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 028111516

Country of ref document: CN

Ref document number: 2003500048

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002735939

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002735939

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10478849

Country of ref document: US